Dr William O Bell, MD | |
152 E Kinderton Way Ste 101, Advance, NC 27006 | |
(336) 893-3190 | |
Not Available |
Full Name | Dr William O Bell |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 152 E Kinderton Way Ste 101, Advance, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487625489 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | 29217 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr William O Bell, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: () - | Dr William O Bell, MD 152 E Kinderton Way Ste 101, Advance, NC 27006 Ph: (336) 893-3190 |
News Archive
A new implantable sensor device provides a less-invasive alternative for monitoring pressure within the skull (intracranial pressure, or ICP), suggests a pilot study in Operative Neurosurgery, a quarterly supplement to Neurosurgery, official journal of the Congress of Neurological Surgeons.
In a new study available on the bioRxiv preprint server, a group of researchers from China report on the pilot-scale production of a purified inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus vaccine candidate (PiCoVacc), shown to induce virus-specific neutralizing antibodies in rats, mice, and non-human primates.
Skinvisible, Inc. has announced that it has been granted a comprehensive patent in Japan for Invisicare, a product-enhancing polymer delivery system for topical dermatology products. The patent protects Invisicare in the areas of 'Topical Composition,' 'Topical Composition Precursor,' and 'Methods for Manufacturing and Using.'
Scientists in the United States have carried out a review of research to determine the link between persistent HPV (human papillomavirus) infection and cervical cancer.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.
› Verified 4 days ago